Crossmark

Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2020-000609

Published Online: 2020-10-13

Published Print: 2020-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Wang, Yungang

Ding, Yanxia

Deng, Yijun

Zheng, Yu

Wang, Shengjun https://orcid.org/0000-0001-6584-1183
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03373188 at ClinicalTrials.gov

Documents that mention this clinical trial

Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer
https://doi.org/10.1136/jitc-2020-000609

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Funding

Funding for this research was provided by:

Jiangsu Province's Key Medical Talents Program (ZDRCB2016018)

Excellent Research Talents Cultivation Fund Program of The First People’s Hospital of Yancheng City (QN2018001)

National Science Foundation of China (81902906)

Jiangsu Province’s Medical Scientific Research Project (H2019102)

Yancheng City’s Medical science and Technology program (YK2018004)

Research Project of Jiangsu Commission of Health (K2019019)
License Information

License valid from 2020-10-13